Page 327 - Multidisipliner Covid 19

COVID-19'da Ba¤›fl›kl›k Yan›tlar› ve Yang›sal Olaylar

of SARS-CoV-2 during an outbreak in Iran: Comparisonwith SARS
and MERS. RevMedVirol. 2020;30(3):e2107.
15. Prompetchara E, Ketloy C, Palaga T. Immuneresponses in COVID-19
andpotentialvaccines: Lessonslearnedfrom SARS and MERS epidemic.
AsianPac J AllergyImmunol. 2020;38(1):1-9.
16. Barnes BJ, Adrover JM, Baxter-Stoltzfus A, et al. Targetingpotentialdriv-
ers of COVID-19: Neutrophilextracellulartraps. J ExpMed. 2020;217(6):
e20200652.
17. Li X, Geng M, Peng Y, Meng L, Lu S. Molecularimmunepathogenesi-
sanddiagnosis of COVID-19. J Pharm Anal. 2020;10(2):102-108. doi:10.
1016/j.jpha.2020.03.001
18. Yazdanpanah F, Hamblin MR, Rezaei N. Theimmunesystemand COVID-
19: Friendorfoe?. Life Sci. 2020;256:117900.
19. Li G, Chen X, Xu A. Profile of specificantibodiestothe SARS-associated-
coronavirus. N Engl J Med. 2003;349(5):508-509.
20. Long QX, Liu BZ, Deng HJ, et al. Antibodyresponsesto SARS-CoV-2
in patientswith COVID-19. NatMed. 2020 (in press).
21. Azkur AK, Akdis M, Azkur D, et al. Immuneresponseto SARS-CoV-2
andmechanisms of immunopathologicalchanges in COVID-19. Allergy.
2020;10.1111/all.14364.
22. Xu Z, Shi L, Wang Y, et al. Pathologicalfindings of COVID-19 associat-
edwithacuterespiratorydistresssyndrome[publishedcorrectionappears
in LancetRespirMed. 2020 Feb 25;:]. LancetRespirMed. 2020;8(4):420-
422.
23. Giamarellos-Bourboulis EJ, Netea MG, Rovina N, et al. ComplexIm-
muneDysregulation in COVID-19 Patientswith Severe RespiratoryFail-
ure. Cell Host Microbe. 2020;27(6):992-1000.
24. Wan S, Yi Q, Fan S, et al. Relationshipsamonglymphocytesubsets,
cytokines, andthepulmonaryinflammationindex in coronavirus (COVID-
19) infectedpatients. Br J Haematol. 2020;189(3):428-437.
25. Tufan A, Avanoğlu Güler A, Matucci-Cerinic M. COVID-19, immunesys-
temresponse, hyperinflammationandrepurposingantirheumaticdrugs.
Turk J MedSci. 2020;50(SI-1):620_632. Published 2020 Apr 21. doi:10.3906/
sag-2004-168
26. Wu D, Yang XO. TH17 responses in cytokinestorm of COVID-19: An
emergingtarget of JAK2 inhibitorFedratinib. J MicrobiolImmunolInfect.
2020;53(3):368-370.

326